Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
about
Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
P2860
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
@en
type
label
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
@en
prefLabel
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
@en
P2860
P50
P1476
Ibrutinib-A double-edge sword in cancer and autoimmune disorders
@en
P2093
Anders Osterborg
Håkan Mellstedt
P2860
P304
P356
10.3109/1061186X.2015.1086357
P577
2015-09-11T00:00:00Z